慢性腎臓病による高リン酸塩血症:治療薬開発パイプライン動向(2016年下半期版)

◆英語タイトル:Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016
◆商品コード:DATA70209346
◆発行会社(調査会社):Global Markets Direct
◆発行日:2016年12月30日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における慢性腎臓病による高リン酸塩血症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・慢性腎臓病による高リン酸塩血症の概要
・慢性腎臓病による高リン酸塩血症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・慢性腎臓病による高リン酸塩血症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・慢性腎臓病による高リン酸塩血症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・慢性腎臓病による高リン酸塩血症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia In Chronic Kidney Disease Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease – Overview 8
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease – Comparative Analysis 9
Hyperphosphatemia In Chronic Kidney Disease – Therapeutics under Development by Companies 10
Hyperphosphatemia In Chronic Kidney Disease – Therapeutics under Investigation by Universities/Institutes 11
Hyperphosphatemia In Chronic Kidney Disease – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia In Chronic Kidney Disease – Products under Development by Companies 15
Hyperphosphatemia In Chronic Kidney Disease – Products under Investigation by Universities/Institutes 16
Hyperphosphatemia In Chronic Kidney Disease – Companies Involved in Therapeutics Development 17
3SBio Inc 17
Ardelyx Inc 18
Daiichi Sankyo Company Ltd 19
Medice Arzneimittel Putter GmbH & Co KG 20
OPKO Health Inc 21
PDX Pharmaceuticals LLC 22
Shield Therapeutics Plc 23
Spectrum Pharmaceuticals Inc 24
Toray Industries Inc 25
Hyperphosphatemia In Chronic Kidney Disease – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
DS-2330 – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
fermagate – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
JPH-101 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
niacinamide – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
PDX-004 – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PT-20 – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
RDX-002 – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
sevelamer carbonate – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SPI-014 – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
tenapanor hydrochloride – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TRK-390 – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
VS-501 – Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Hyperphosphatemia In Chronic Kidney Disease – Dormant Projects 51
Hyperphosphatemia In Chronic Kidney Disease – Discontinued Products 52
Hyperphosphatemia In Chronic Kidney Disease – Product Development Milestones 53
Featured News & Press Releases 53
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia 53
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 54
Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation 54
May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb 55
Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc, H2 2016 17
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H2 2016 18
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 19
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H2 2016 20
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H2 2016 21
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H2 2016 22
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H2 2016 23
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 24
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries Inc, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2016 51
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2016 52

List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Top 10 Targets, H2 2016 27
Number of Products by Stage and Top 10 Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

【レポートのキーワード】

慢性腎臓病による高リン酸塩血症

★調査レポート[慢性腎臓病による高リン酸塩血症:治療薬開発パイプライン動向(2016年下半期版)] (コード:DATA70209346)販売に関する免責事項を必ずご確認ください。
★調査レポート[慢性腎臓病による高リン酸塩血症:治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆